Natus Medical (NASDAQ:NTUS) Announces Earnings Results, Misses Estimates By $0.04 EPS

Natus Medical (NASDAQ:NTUSGet Rating) announced its earnings results on Thursday. The company reported $0.22 EPS for the quarter, missing the consensus estimate of $0.26 by ($0.04), MarketWatch Earnings reports. Natus Medical had a return on equity of 9.75% and a net margin of 2.78%. During the same quarter last year, the firm earned $0.16 earnings per share.

Shares of NASDAQ NTUS traded down $0.09 during mid-day trading on Friday, reaching $32.95. The company had a trading volume of 328,093 shares, compared to its average volume of 904,870. The company has a market capitalization of $1.14 billion, a price-to-earnings ratio of 89.06 and a beta of 0.23. The stock has a fifty day moving average of $28.07 and a two-hundred day moving average of $25.53. Natus Medical has a 12-month low of $20.90 and a 12-month high of $33.93.

Hedge funds have recently added to or reduced their stakes in the business. BlackRock Inc. increased its position in Natus Medical by 2.0% in the 4th quarter. BlackRock Inc. now owns 6,558,137 shares of the company’s stock worth $155,625,000 after purchasing an additional 126,819 shares during the last quarter. Geode Capital Management LLC raised its position in Natus Medical by 2.7% during the fourth quarter. Geode Capital Management LLC now owns 606,152 shares of the company’s stock valued at $14,383,000 after acquiring an additional 15,863 shares in the last quarter. Charles Schwab Investment Management Inc. raised its position in Natus Medical by 8.6% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 420,806 shares of the company’s stock valued at $9,986,000 after acquiring an additional 33,351 shares in the last quarter. Bank of New York Mellon Corp grew its position in Natus Medical by 2.0% in the third quarter. Bank of New York Mellon Corp now owns 320,947 shares of the company’s stock worth $8,049,000 after acquiring an additional 6,281 shares in the last quarter. Finally, Norges Bank acquired a new position in shares of Natus Medical during the 4th quarter worth $6,583,000. Institutional investors own 92.35% of the company’s stock.

Several brokerages recently commented on NTUS. StockNews.com initiated coverage on shares of Natus Medical in a research report on Thursday, March 31st. They issued a “strong-buy” rating for the company. Zacks Investment Research cut Natus Medical from a “buy” rating to a “hold” rating in a research report on Tuesday.

Natus Medical Company Profile (Get Rating)

Natus Medical Incorporated provides medical device solutions focuses on the diagnosis and treatment of patients with central nervous and sensory system disorders worldwide. It offers products and technologies used for the screening, detection, treatment, monitoring, and tracking of common medical ailments in newborn care, hearing impairment, neurological and neurosurgical treatments, epilepsy, sleep disorders, and neuromuscular diseases.

Further Reading

Earnings History for Natus Medical (NASDAQ:NTUS)

Receive News & Ratings for Natus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical and related companies with MarketBeat.com's FREE daily email newsletter.